Loading...
Akero Therapeutics reported third quarter financial results with focus on advancing efruxifermin (EFX) through Phase 2b clinical trials for NASH treatment.
Focused on completing two Phase 2b clinical trials.
Diligently working with regulators to bring efruxifermin (EFX) to market.
Received Fast Track designation from the FDA.
EFX is being evaluated in the HARMONY and SYMMETRY studies.
Forward-looking statements involve risks and uncertainties, and actual results may differ materially.
Analyze how earnings announcements historically affect stock price performance